ClinicalTrials.Veeva
Menu

Find clinical trials for Asthma in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Allergic Rhinitis
Nasal Polyps
Rhinitis
Rhinosinusitis
Sinusitis
Conjunctivitis

Asthma trials near Warszawa, Mazowieckie, POL:

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. (EXHALE-2)

This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma...

Enrolling
Asthma
Asthma; Eosinophilic
Drug: Placebo
Drug: Dexpramipexole Dihydrochloride

Phase 3

Areteia Therapeutics

Warsaw, Poland and 331 other locations

The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma...

Active, not recruiting
Asthma Attack
Asthma; Eosinophilic
Drug: Dexpramipexole Dihydrochloride
Drug: Placebo

Phase 3

Areteia Therapeutics

Piaseczno, Poland and 314 other locations

Locations recently updated

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Enrolling
Moderate to Severe Asthma
Drug: ICS-LABA
Other: placebo

Phase 2

Incyte
Incyte

Warszawa, Poland and 84 other locations

The goal of this clinical trial\] is to evaluate the long term safety of dexpramipexole treatment in participants with severe asthma, aged ≥...

Invitation-only
Eosinophilic Asthma
Drug: Dexpramipexole Dihydrochloride

Phase 3

Areteia Therapeutics

Piaseczno, Poland and 62 other locations

Locations recently updated

treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted i...

Enrolling
Asthma
Wheezing
Drug: Placebo
Drug: Dupilumab

Phase 3

Sanofi
Sanofi

Warsaw, Poland and 68 other locations

and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma...

Enrolling
Asthma
Drug: Placebo
Drug: Atuliflapon

Phase 2

AstraZeneca
AstraZeneca

Warszawa, Poland and 382 other locations

inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs).Secondary Objectives:To evaluate the efficacy...

Enrolling
Asthma
Drug: Albuterol sulfate
Drug: TEV-56248

Phase 3

Teva Pharmaceuticals
Teva Pharmaceuticals

Warszawa, Poland and 361 other locations

expiratory volume (FEV1) \[PC20\]) of salbutamol administered via MDI with salbutamol HFA-134a or salbutamol HFA-152a in participants with mild asthma...

Enrolling
Asthma
Mild Asthma
Drug: Salbutamol HFA-134a
Drug: Salbutamol HFA-152a

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Jozefow, Poland and 9 other locations

birch pollen-induced allergic rhinoconjunctivitis, with or without asthma, when treated before and during the pollen season.Approximately 69...

Active, not recruiting
Birch Pollen Allergy
Allergic Rhinoconjunctivitis
Drug: STALORAL® Birch 300 IR

Phase 3

Stallergenes Greer
Stallergenes Greer

Warsaw, Poland and 61 other locations

months.Trial population: Patients (18-65 years of age) suffering from moderate to severe ARC induced by HDM with or without controlled asthma...

Active, not recruiting
House Dust Mite Rhinitis
House Dust Mite Allergy
Biological: PURETHAL Mites 50,000 AUeq/ml
Biological: Biological/Vaccine: Placebo

Phase 3

HAL Allergie

Warszawa, Poland and 67 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems